GSK vs. SHEL
Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Shell plc (SHEL).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GSK or SHEL.
Correlation
The correlation between GSK and SHEL is 0.45, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GSK vs. SHEL - Performance Comparison
Loading data...
Key characteristics
GSK:
-0.50
SHEL:
-0.14
GSK:
-0.60
SHEL:
-0.16
GSK:
0.93
SHEL:
0.98
GSK:
-0.50
SHEL:
-0.29
GSK:
-0.87
SHEL:
-0.68
GSK:
16.52%
SHEL:
7.93%
GSK:
27.30%
SHEL:
23.03%
GSK:
-54.70%
SHEL:
-67.46%
GSK:
-15.29%
SHEL:
-8.12%
Fundamentals
GSK:
$76.30B
SHEL:
$199.89B
GSK:
$2.03
SHEL:
$4.38
GSK:
18.51
SHEL:
15.39
GSK:
0.38
SHEL:
1.48
GSK:
2.42
SHEL:
0.71
GSK:
4.05
SHEL:
1.12
GSK:
$31.53B
SHEL:
$281.07B
GSK:
$22.56B
SHEL:
$42.59B
GSK:
$8.24B
SHEL:
$54.83B
Returns By Period
In the year-to-date period, GSK achieves a 12.31% return, which is significantly higher than SHEL's 8.63% return. Over the past 10 years, GSK has outperformed SHEL with an annualized return of 6.28%, while SHEL has yielded a comparatively lower 5.85% annualized return.
GSK
12.31%
6.22%
13.89%
-13.60%
7.40%
6.28%
SHEL
8.63%
5.16%
3.95%
-3.22%
21.95%
5.85%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
GSK vs. SHEL — Risk-Adjusted Performance Rank
GSK
SHEL
GSK vs. SHEL - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Shell plc (SHEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
GSK vs. SHEL - Dividend Comparison
GSK's dividend yield for the trailing twelve months is around 4.27%, more than SHEL's 4.21% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 4.27% | 4.60% | 3.75% | 4.78% | 6.14% | 6.86% | 5.34% | 6.93% | 7.13% | 8.82% | 7.43% | 7.60% |
SHEL Shell plc | 4.21% | 4.39% | 3.76% | 3.48% | 3.78% | 5.44% | 6.14% | 5.48% | 4.79% | 5.88% | 6.98% | 4.72% |
Drawdowns
GSK vs. SHEL - Drawdown Comparison
The maximum GSK drawdown since its inception was -54.70%, smaller than the maximum SHEL drawdown of -67.46%. Use the drawdown chart below to compare losses from any high point for GSK and SHEL. For additional features, visit the drawdowns tool.
Loading data...
Volatility
GSK vs. SHEL - Volatility Comparison
GlaxoSmithKline plc (GSK) has a higher volatility of 8.43% compared to Shell plc (SHEL) at 5.52%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than SHEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
GSK vs. SHEL - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Shell plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK vs. SHEL - Profitability Comparison
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a gross profit of 5.58B and revenue of 7.52B. Therefore, the gross margin over that period was 74.2%.
SHEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Shell plc reported a gross profit of 12.71B and revenue of 69.23B. Therefore, the gross margin over that period was 18.4%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported an operating income of 2.22B and revenue of 7.52B, resulting in an operating margin of 29.5%.
SHEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Shell plc reported an operating income of 9.47B and revenue of 69.23B, resulting in an operating margin of 13.7%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, GlaxoSmithKline plc reported a net income of 1.62B and revenue of 7.52B, resulting in a net margin of 21.6%.
SHEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Shell plc reported a net income of 4.78B and revenue of 69.23B, resulting in a net margin of 6.9%.